Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
FDA clearance is in place for a Phase 1/2 study, which Actuate plans to initiate in Q1 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Actuate Therapeutics (NASDAQ: ACTU) will present preclinical results for oral elraglusib in a mouse melanoma model at ENA 2026. Daily treatment with the tablet alone significantly inhibited tumor growth and showed favorable tolerability in the aggressive B16F10 model. Tumors had increased CD8+ T cells and natural killer cells, which help attack tumors, and fewer myeloid-like cells associated with immune suppression.
The poster presentation is scheduled for November 18, 2026, in Barcelona. The FDA cleared the application for a Phase 1/2 trial in advanced solid tumors in May 2026. Actuate plans to initiate the trial in Q1 2027, initially testing the tablet alone in patients with metastatic melanoma. The company views the mouse findings as support for advancing the oral formulation into clinical studies; these results are preclinical, not patient outcomes.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFDA cleared the investigational trial application in May 2026 for oral elraglusib in advanced solid tumors.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Actuate plans Phase 1/2 trial initiation in Q1 2027, initially testing monotherapy in metastatic melanoma.
- Minor pointDaily oral elraglusib alone significantly inhibited tumor growth in the B16F10 mouse melanoma model.
- Minor pointOral elraglusib demonstrated favorable tolerability in the mouse study.
- Minor pointTreated tumors showed increased CD8+ T cells and natural killer cells and fewer immune-suppressive myeloid-like cells.
- Minor point. Forward-looking: it has not happened yet and may not happen.Actuate identifies potential trial expansion into non-small cell lung cancer, colorectal cancer and pancreatic cancer.
Negative
- None.
Details
Market move: ACTU +5.69% in the Nov 4 session. preclinical melanoma data
On Nov 4, the day this news came out, ACTU closed 5.69% above the previous close. Argus tracked a peak move of +2.8% during that session. Our momentum scanner recorded 5 alerts for this stock that day.
Data tracked by StockTitan Argus for the Nov 4 session.
Key Figures
- Trial initiation
- Q1 2027
- Planned Phase 1/2 oral elraglusib trial, initially in metastatic melanoma
- IND clearance
- May 2026
- FDA cleared the Investigational New Drug application for the oral elraglusib Phase 1/2 study
Historical Context
-
Patent claims covering oral elraglusib tablets were allowed; Phase 1/2 trial planned for Q1 2027.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
syngeneic medical
immunophenotyping medical
monotherapy medical
investigational new drug regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Oral tablet formulation of elraglusib as a monotherapy significantly inhibited tumor growth and
enhanced antitumor immune activity in an aggressive, poorly immunogenic melanoma model
- Phase 1/2 clinical trial evaluating Elraglusib Oral Tablet to be initiated in Q1 2027
CHICAGO and FORT WORTH, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that new preclinical data evaluating oral elraglusib will be presented in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), taking place November 18-20, 2026, in Barcelona, Spain.
The study evaluated Elraglusib Oral Tablet as a single agent in the B16F10 syngeneic melanoma model, a poorly immunogenic, rapidly growing and highly aggressive tumor model. Daily oral administration of elraglusib significantly inhibited tumor growth and demonstrated favorable tolerability. Tumor immunophenotyping demonstrated that elraglusib treatment increased the accumulation of CD8+ T cells and natural killer (NK) cells within tumors while decreasing myeloid-like tumor suppressor cells (Ly6G+ neutrophil/PMN-MDSC-like) associated with an immunosuppressive tumor microenvironment.
The findings provide the first in vivo evidence of both direct antitumor activity and immunomodulatory effects of Elraglusib Oral Tablet in an immunocompetent mouse tumor model, suggesting that treatment can alter the tumor microenvironment dynamics from a less myeloid-suppressive state toward a more active immune state.
“This preclinical work further supports the mechanism of action for elraglusib and demonstrates that the higher exposures achieved with daily dosing of the Elraglusib Oral Tablet elicit direct antitumor activity and favorable immune cell dynamics within the tumor microenvironment, leading to robust inhibition of tumor growth in this aggressive B16F10 melanoma model,” said Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics. “We believe these findings, including the reduction of myeloid-mediated immune suppression that makes poorly immunogenic tumors difficult to treat, support advancing elraglusib tablets into clinical studies as a single agent in patients with refractory metastatic melanoma.”
Poster Presentation Details
Title: Evaluation of antitumor activity of oral elraglusib in B16F10 melanoma model
Presenting Author: Andrey Ugolkov, MD, PhD, Actuate Therapeutics
Poster Number: PB-142, Exhibition Hall poster area A
Session: Translational Studies
Date: November 18, 2026
The poster will be available on Actuate’s website following its presentation at the symposium.
In May 2026, the U.S. Food and Drug Administration cleared Actuate's Investigational New Drug application for a Phase 1/2 study of oral elraglusib tablets in patients with advanced solid tumors. The study is planned for initiation in early 2027, initially focusing on treatment of patients with metastatic melanoma as a monotherapy, with potential to expand the trial into treatment of patients with non-small cell lung cancer, colorectal cancer, and pancreatic cancer.
Elraglusib has previously been evaluated as an IV formulation in other cancers, including clinical studies in patients with metastatic pancreatic ductal adenocarcinoma, Ewing Sarcoma and refractory neuroblastoma.
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in activation of anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function in addition to targeting those promoting tumor growth and resistance to conventional chemotherapy.
For additional information, please visit the Company’s website at www.actuatetherapeutics.com or follow us on LinkedIn, X, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the expectations for the planned Phase1/2 clinical study of the Elraglusib Oral Tablet based on the results of the Company’s preclinical B16F10 syngeneic melanoma model study; the anticipated timing and design of a Phase 1/2 clinical trial of the Elraglusib Oral Tablet, and the potential benefits of oral elraglusib, including its potential to enhance antitumor activity, improve patient convenience and expand therapeutic applications. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including (i) success in early phases of preclinical clinicals trials do not ensure later clinical trials will be successful, (ii) the risk that we may not be able to commence or complete our expected Phase 1/2 trial of Elraglusib Oral Tablet or, if we can, that the Phase 1/2 trial may not produce positive results; (iii) the risk that the Company may not be able to obtain additional working capital with which to complete the Phase 1/2 clinical trial, or advance to the initiation of registration-enabling studies, for Elraglusib Oral Tablet as and when needed and (iv) those other risks disclosed under the caption “Risk Factors” in Actuate’s Annual Report of Form 10-K filed with the Securities and Exchange Commission on March 26, 2026 and in Actuate’s subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Actuate does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Media Contact
Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Actuate's oral elraglusib melanoma study show?
Daily oral elraglusib alone significantly inhibited tumor growth and demonstrated favorable tolerability in the B16F10 mouse melanoma model. Treated tumors showed increased CD8+ T cells and natural killer cells, alongside fewer myeloid-like cells associated with immune suppression. These were preclinical findings.
When does Actuate plan to start the oral elraglusib clinical trial?
Actuate plans to initiate the Phase 1/2 trial in Q1 2027, initially evaluating oral elraglusib alone in patients with metastatic melanoma. The FDA cleared the investigational application for a study in advanced solid tumors in May 2026.
Which other cancers could Actuate's oral elraglusib trial expand into?
The planned trial could expand into non-small cell lung cancer, colorectal cancer and pancreatic cancer. These are potential expansions, rather than confirmed trial cohorts.